$ICU

New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)

SeaStar Medical (ICU) announced new ICD-10-PCS codes for its SCD therapy in treating acute kidney injury (AKI). The codes streamline hospital billing and expand access to QUELIMMUNE therapy. The company expects this to support broader adoption and potential future indications. QUELIMMUNE showed a 77% survival rate in clinical trials, with no dialysis required for survivors.

Original reporting
Published Oct 1, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$ICU
Bullish
high confidence
Mentioned
$ICU
Relevance
7/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$ICUBullishMed
01

Why it matters

The coding update is a regulatory/administrative milestone that could accelerate market penetration and improve financial outlook.

02

Market read

First‑time disclosure of billing codes removes a commercial barrier, likely supporting ICU stock and related medical‑device peers.

03

What to watch

Reimbursement negotiations with payors and the need for FDA approvals for adult indications could temper the impact.

Relevance 7/10Novelty 7/10Timing: effective today

Background

SeaStar Medical Holding Corp (ICU) is a commercial‑stage company with the only FDA‑approved therapy for pediatric AKI. The new ICD‑10‑PCS codes address previous billing limitations.

Company-level read

Ticker impact

$ICUBullishHigh confidence
Context

SeaStar Medical announced new ICD-10-PCS codes for its QUELIMMUNE therapy, enabling billing and tracking for AKI treatment.

Expected impact

likely upward pressure as hospitals can now bill for the therapy, supporting revenue growth

Evidence & confidence

The first disclosure of billing codes removes a key barrier to adoption, which should improve commercial uptake.

Market effects

May boost the broader renal‑replacement therapy and medical‑device sector as coding clarity improves reimbursement prospects.

U.S. hospital billing processes are directly affected; limited immediate impact outside the U.S.

Primarily U.S. focused, with modest relevance to global biotech investors tracking SeaStar.

Counterpoint

If adoption is slower than expected, the coding change may not translate into near‑term revenue, limiting price upside.

Key entities

  • SeaStar Medical Holding Corp

    Developer of QUELIMMUNE therapy and holder of the new ICD‑10‑PCS codes.

  • Centers for Medicare & Medicaid Services (CMS)

    Maintains the ICD‑10‑PCS coding system used for hospital billing.

Related articles

$ICUHighAI 8/10

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

SeaStar Medical (ICU) received FDA Breakthrough Device Designation for its SCD therapy to treat hyperinflammation in adult sepsis patients. This designation accelerates development and review. Sepsis affects 1.7M U.S. adults annually, with high mortality rates. The company plans to submit data to the FDA soon. This is the seventh such designation for the SCD therapy across various indications.

$ICUMed

SeaStar Medical (ICU) Q2 2026 Earnings Call Transcript

SeaStar Medical Holding Corp (ICU) reported Q2 2026 net revenue of $615,000, up 82% year over year, and six-month net revenue of $1.1 million. Gross margin was 91%. Net loss was $3.7 million ($0.91/share). Cash was $7.0 million at June 30, 2026. QUELIMMUNE adoption reached 20 hospitals; NEUTRALIZE-AKI enrolled 223/339 patients.

$ICUMed

SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates

SeaStar Medical Holding Corp (ICU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates Added 3 top-rated children ’ s hospitals to QUELIMMUNE ® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enro